Immunocidin® Demonstrates Acceptable Safety Profile with IV Use in Dogs and Cats
NovaVive is a private Canadian immunobiology company founded in July, 2014. The Company acquired an advanced veterinary immunotherapeutic platform based on mycobacterium cell wall fraction (MCWF) technology with regulator-approved products for cattle, horses and dogs. These products are currently sold to veterinarians in the U.S.A., Canada, Australia and New Zealand. The Company's head office is located in Napanee, Ontario, Canada.
NovaVive made two presentations at the World Buiatrics Congress in Sapporo, Japan today. Both presentations highlighted efficacy of MCWF in mature dairy cattle. More research is required, but these results are very promising.
learn more
NovaVive Inc. has signed a marketing services agreement with AABEX Animal Health for the U.S.A. AABEX is a new animal health sales and marketing company founded by Mark Hill, a seasoned industry professional from Merial Ltd.
learn more
Dr. Jeannette Kelly, veterinary oncologist with Veterinary Cancer Care, presented data from a study of multiple IV administrations of Immunocidin® in dogs and cats with various malignancies at the ACVIM Forum last week.
learn more
